Even friends have disputes over money sometimes. That's what's happening with PDL BioPharma and Roche's Genentech: PDL wants to take Genentech to arbitration for underpaying royalties, the AP reports.
The company, which includes Genentech legend Art Levinson on its board, has been engaged in basic scientific research for the past 5 years, with a special focus on cardio/metabolic work.
Symphogen has replenished its coffers with 41 million euros ($53.7 million) as the Danish biotech makes progress with next-generation antibody drugs for treating cancer. The latest capital infusion adds to 100 million euros ($130.9 million) that the company previously raised in 2011 for the round, giving the company about 100 million euros in cash as of today, according to the group's press release.
Genentech has stepped into the spotlight at the annual meeting of the American Association for Cancer Research, armed with promising data from a small early-stage study of a new immunotherapy cancer drug.
Mobile has gone mainstream in the biopharma industry, at least for those who work as tablet-toting sales reps or other jobs that take them away from the office. Read more >>
With the first knockoffs of biotech drugs in the U.S. expected in the coming years, providers of the novel biologics such as Amgen and Genentech have pushed for state legislation that makes doctors and pharmacies clear hurdles before approved biosimilars are used in place of the originals.
We've seen plenty of acrimony from the biotech communities in the U.S. and Europe over the insufficient venture capital dollars for young drug developers. Read more >>
Facebook CEO and founder Mark Zuckerberg has sought out a top Genentech alum for the social media giant's board of directors.
Dako has been on a tear with big-name companion diagnostics partnerships, and its latest one might end up being the most lucrative: The company has received FDA approval for two tests to be paired with Kadcyla, Roche's soon-to-explode breast cancer drug.
BIO analysts recently noted that only about one out of every 20 new oncology candidates went on to an approval in the past decade, and that 5% success ratio could have been overly generous.